ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-11-14

Summary

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

• Phase: EARLY_PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: adagrasib; Bevacizumab; Cetuximab; encorafenib; Folfox protocol; IFL protocol; Panitumumab; sotorasib; Standard of Care; tipiracil; trastuzumab deruxtecan; Trifluridine; trifluridine tipiracil drug combination; tucatinib